BioScrip to Participate in Upcoming Investor Conferences
21 Mai 2019 - 3:00PM
BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, today announced that Daniel E. Greenleaf,
President and Chief Executive Officer, and Stephen M. Deitsch,
Senior Vice President, Chief Financial Officer and Treasurer, will
participate in the following upcoming investor conferences:
The 16th Annual Craig-Hallum Institutional Investor
ConferenceMinneapolis, MinnesotaWednesday, May 29,
2019One-on-one and small group meetings only
The Jefferies 2019 Healthcare ConferenceNew
York, New YorkTuesday, June 4, 2019Group presentation – 2:00 p.m.
ET One-on-one and small group meetings throughout the day
Given BioScrip’s pending combination with Option Care, Option
Care’s Chief Executive Officer, John Rademacher, and Chief
Financial Officer, Mike Shapiro, plan to accompany BioScrip’s
senior leadership at these events. A live webcast of the
Jefferies group presentation and copies of the materials presented
can be accessed via BioScrip’s Investor Relations website at
https://investors.bioscrip.com/ or through the following link:
http://wsw.com/webcast/jeff118/bios/.
About BioScrip, Inc.
BioScrip, Inc. is the largest independent
national provider of infusion and home care management solutions,
with approximately 2,100 teammates and nearly 70 service locations
across the U.S. BioScrip partners with physicians, hospital
systems, payors, pharmaceutical manufacturers and skilled nursing
facilities to provide patients access to post-acute care services.
BioScrip operates with a commitment to bring customer-focused
pharmacy and related healthcare infusion therapy services into the
home or alternate-site setting. By collaborating with the full
spectrum of healthcare professionals and the patient, BioScrip
provides cost-effective care that is driven by clinical excellence,
customer service, and values that promote positive outcomes and an
enhanced quality of life for those it serves.
ADDITIONAL INFORMATION AND WHERE TO FIND IT
On April 30, 2019, BioScrip, Inc. (“BioScrip” or
the “Company”) filed with the Securities and Exchange Commission
(“SEC”) a preliminary proxy statement in connection with the
proposed transaction. The definitive proxy statement will be sent
to the stockholders of BioScrip and will contain important
information about the proposed transaction and related
matters. INVESTORS AND SECURITY HOLDERS ARE URGED AND ADVISED
TO READ THE PRELIMINARY PROXY STATEMENT AND THE DEFINITIVE PROXY
STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN
IMPORTANT INFORMATION. The proxy statement and other relevant
materials (when they become available) and any other documents
filed by the Company with the SEC may be obtained free of charge at
the SEC’s website, at www.sec.gov. In addition, security
holders will be able to obtain free copies of the proxy statement
and other relevant materials from the Company by contacting
Investor Relations by mail at 1600 Broadway, Suite 700, Denver, CO
80202, Attn: Investor Relations, by telephone at (720) 697-5200, or
by going to the Company’s Investor Relations page on its corporate
web site at https://investors.bioscrip.com.
PARTICIPANTS IN THE SOLICITATION
The Company and its directors and executive
officers may be deemed to be participants in the solicitation of
proxies from stockholders in connection with the matters discussed
above. Information about the Company’s directors and executive
officers is set forth in the Proxy Statement on Schedule 14A for
the Company’s 2019 annual meeting of stockholders, which was filed
with the SEC on April 30, 2019. This document can be obtained
free of charge from the sources indicated above. Information
regarding the ownership of the Company’s directors and executive
officers in the Company’s securities is included in the Company’s
SEC filings on Forms 3, 4, and 5, which can be found through the
SEC’s website at www.sec.gov. Other information regarding the
participants in the proxy solicitation and a description of their
direct and indirect interests, by security holdings or otherwise,
is contained in the preliminary proxy statement and will be
contained in the definitive proxy statement and other relevant
materials to be filed with the SEC when they become available.
Investor Contacts:
Stephen Deitsch |
|
|
|
Kalle Ahl, CFA |
Chief Financial Officer & Treasurer |
|
|
|
The Equity Group |
T: (720) 697-5200 |
|
|
|
T: (212) 836-9614 |
stephen.deitsch@bioscrip.com |
|
|
|
kahl@equityny.com |
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Août 2023 à Août 2024